Author:
Juárez-Hernández Eva,Velázquez-Alemán Alain P.,Castro-Narro Graciela,Uribe Misael,López-Méndez Iván
Abstract
Nowadays, non-alcoholic fatty liver disease is one of the first causes of liver transplant worldwide; many efforts have been done to find the perfect drug for this multifactorial disease. Presently we just have a few drugs that could be used in specific and limited clinical scenarios. Current evidence suggests that bariatric endoscopic and surgical therapies could be strategies with optimal outcomes, with high impact in quality of life, decrease of cardiovascular risk, and improvement in metabolic profile, despite being considered expensive procedures. This review proposes to consider these therapies early together with liver fibrosis evaluation, with long term cost-effectiveness benefits in the absence of response to lifestyle modifications and pharmacological treatments.
Subject
Endocrinology, Diabetes and Metabolism
Reference78 articles.
1. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease;Estes;Hepatology,2018
2. Prevalence trends in non-alcoholic fatty liver disease at the global, regional and national levels, 1990-2017: a population-based observational study;Ge;BMJ Open,2020
3. Non-alcoholic fatty liver disease;Maurice;Clin Med J R Coll Physicians London,2018
4. Global epidemiology of nonalcoholic fatty liver disease–meta-analytic assessment of prevalence, incidence, and outcomes;Younossi;Hepatology,2016
5. [State of the art on the pathophysiology, diagnosis and treatment of non-alcoholic steatohepatitis (NASH)];Grzych;Ann Pharm Fr,2022
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献